A subset of tumor-specific somatic alterations generate neoantigens that bind to MHC molecules and are presented directly on the tumor cell’s surface and by professional antigen-presenting cells (APCs) for recognition by T cells1. This evidence concerns the gene HLA-C and neoplasm.